RNAi News and Research

RSS

Researchers identify new genes necessary for embryonic development

Researchers at New York University and the medical schools at Harvard and Yale universities have identified new genes necessary for embryonic development, according to findings published in the latest issue of Genome Research.

31 Jan 2005

Scientists discover that microRNAs regulate thousands of human genes

For many years, DNA and proteins have been viewed as the real movers and shakers in genomic studies, with RNA seen as little more than a messenger that shuttles information between the two.

16 Jan 2005

First program to apply RNA interference (RNAi) technology to asthma

Sirna Therapeutics, Inc. has announced the first program to apply RNA interference (RNAi) technology to asthma, a highly prevalent, chronic disease accounting for an estimated $13 billion in healthcare costs in the United States, a number which is forecast to grow considerably by the end of the decade.

7 Jan 2005

Next-generation therapeutics with the potential to successfully treat Lou Gehrig's disease

The hopes of many that ALS (commonly referred to as Lou Gehrig's disease) will one day be a disease of the past, studied in medical textbooks, conquered by the dedication of those who have worked tirelessly to eradicate it might be realized in our lifetime.

6 Dec 2004

Temperature sensing protein implicated in mediating thermotaxis

The songwriter Noel Coward once declared that only mad dogs and Englishmen went out in the midday sun. MIT biologists Mark Rosenzweig, Paul Garrity and their colleagues now have a third candidate for the lyric—fruit flies with defects in a gene called dTrpA1.

4 Dec 2004

Blocking gene opens avenues for treating prostate cancer

Cancer Research UK scientists in Oxford have found a new way to make prostate cancer succumb more readily to currently used treatments.

22 Oct 2004

Benitec receives exclusive rights to use DNA technology pioneered at Stanford University for all RNAi therapeutic uses

Benitec has announced an exclusive licensing deal with Stanford University. Under the license, Benitec receives exclusive rights to use the Minicircle DNA technology pioneered at Stanford University for all RNAi therapeutic uses, with sub-licensing rights.

18 Oct 2004

Genetic science gaining momentum by silencing genes

Along with five European academic laboratories, researchers from the Flanders Interuniversity Institute for Biotechnology (VIB) connected to Ghent University are accelerating the study of the model plant Arabidopsis thaliana.

16 Oct 2004

RNAi enlisted in hunt for prawn vaccines

CSIRO researchers are using a biological phenomenon called RNA interference (RNAi) in an effort to develop a major biotechnological breakthrough for the aquaculture industry - vaccines for common prawn diseases.

16 Sep 2004

Advances in gene silencing on the agenda

Recent advances in using 'RNA interference' (RNAi) to improve plant, animal and human health will be the major focus of the CSIRO-hosted Horizons in Livestock Sciences Conference on the Gold Coast from 12-15 September.

8 Sep 2004

Study on RNAi technology targeting neurodegenerative diseases

Sirna Therapeutics has announced the publication of preclinical studies evaluating RNA interference-based therapies for a class of inherited neurodegenerative diseases of the central nervous system (CNS) in the current issue of Nature Medicine.

16 Aug 2004

Total global market for oligonucleotides is likely to grow from USD 340.0 million in 2003 to USD 776.0 million in 2010

Poised on the brink of phenomenal growth, the oligonucleotides market offers a plethora of opportunities to the enterprising investor. Recent analysis by Frost & Sullivan estimates that the total global market for oligonucleotides is likely to grow from USD 340.0 million in 2003 to USD 776.0 million in 2010.

9 Aug 2004

Market research 'World RNAi Markets: Current and Future Outlook'

Gene silencing by RNAi has now been identified as a crucial technology for target validation and therapeutics. By targeting and interfering with messenger RNA (mRNA), RNAi technology blocks the expression of the proteins implicated in disease progression.

19 Jul 2004

Lou Gehrig's disease may be treated or even prevented

Tripping, stumbling, falling, slow, steady loss of muscle control and strength in hands and feet, difficulty speaking, swallowing and breathing...

28 Jun 2004

SARS siRNA studied further to help many respiratory diseases including lung cancer

Intradigm Corporation, has announced achievement of prophylactic and therapeutic effects of siRNA (small interfering RNA) inhibitors of SARS-CoV in non-human primate cells. The results are published in the June 2004 issue of Antiviral Therapy (International Medical Press).

15 Jun 2004

Novel molecular targeting technologies to deliver gene-silencing therapy

Researchers have combined novel molecular targeting technologies to deliver gene-silencing therapy specifically to tumor cells shielded by a normally impermeable obstacle, the blood brain barrier.

1 Jun 2004

Benitec acquires Avocel to focus on rapid development of hepatitis C therapeutics

Benitec Ltd. today announced the acquisition of Avocel, Inc. of Sunnyvale, CA, a leading RNAi therapeutics company, and the establishment of its wholly-owned US subsidiary, Benitec, Inc. Through the acquisition, Benitec gains its first in-house advanced therapeutic development program using DNA-directed RNAi (ddRNAi) to target the Hepatitis C virus.

18 May 2004

3 people with drug-resistant HIV become first to undergo a new form of gene therapy

The idea is to use a modified form of HIV to deliver an "antisense" gene to the immune cells that HIV infects. This is integrated into the cells' genome, and stays there until a cell is infected. Then it is switched on, and produces RNA complementary to the "sense" RNA encoding a viral protein. In theory, the RNAs should bind together, blocking viral replication.

14 May 2004

New hope for advances in treatment methods for AIDS, Alzheimer's and age-related blindness

Pharmaceutical science leaders from the FDA, research institutions and top pharmaceutical companies will gather at the 2004 AAPS National Biotechnology Conference, AAPS' spring annual meeting.

4 May 2004

QIAGEN launches human siRNA library sets

Prime Standard QIA a leading supplier of products and technologies for nucleic acid separation, purification and handling today announced that it has launched a series of off-the-shelf human library siRNA sets, covering a broad gene family selection including kinases, GPCRs, apoptosis related genes, and oncogenes, to name a few.

From QIAGEN Manchester Limited 3 May 2004